0OT Stock Chart & Stats
€7.40
€0.05(0.68%)
At close: 4:00 PM EDT
€7.40
€0.05(0.68%)
Day’s Range― - ―
52-Week Range€5.68 - €13.66
Previous CloseN/A
Volume0.00
Average Volume (3M)38.00
Market Cap
€1.61B
Enterprise Value€1.31K
Total Cash (Recent Filing)€666.70M
Total Debt (Recent Filing)€79.46M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 10, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding218,960,360
10 Day Avg. Volume44
30 Day Avg. Volume38
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)3.47
Price to Sales (P/S)43.86
P/FCF Ratio-10.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.10Price Target Upside198.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.4
Revenue Forecast (FY)€45.62M
Bulls Say, Bears Say
Bulls Say
Sustained‑release PlatformOcular Therapeutix’s core bioresorbable hydrogel sustained‑release platform is a structural competitive asset: it enables differentiated product profiles (multi-week delivery), higher switching costs for prescribers, and a reusable technological base to extend into multiple ophthalmic indications over several years.
High Gross MarginsVery high product‑level gross margins indicate attractive unit economics for DEXTENZA and other candidates. Durable gross margin strength supports long‑term profitability potential if scale grows, enabling investment in R&D and commercial expansion without eroding underlying product profitability.
Low Financial LeverageRelatively low leverage provides the company runway to fund near‑term operations or strategic investments without immediate refinancing stress. This structural balance sheet strength improves financial optionality during continued clinical development and commercialization phases.
Bears Say
Large Cash BurnSustained heavy negative operating and free cash flow is a core structural risk: ongoing cash burn erodes liquidity and forces reliance on external financing or dilution. Over 2–6 months this limits strategic flexibility and raises capital‑raising needs if cash generation doesn’t improve.
Very Large Operating LossesExtremely negative margins reflect that operating costs far exceed current revenue. This structural unprofitability means scaling revenue must be sustained and significant to reach breakeven, and persistent large losses will continue to pressure equity value and reinvestment capacity.
Revenue Volatility & Recent DeclineIrregular revenue trends and a recent meaningful decline indicate commercial execution and demand variability risks. For a small commercial biopharma, volatile top‑line undermines margin leveraging and planning, making long‑term forecasting and capital allocation more uncertain.
Ocular Therapeutix News
0OT FAQ
What was Ocular Therapeutix Inc’s price range in the past 12 months?
Ocular Therapeutix Inc lowest stock price was €5.68 and its highest was €13.66 in the past 12 months.
What is Ocular Therapeutix Inc’s market cap?
Ocular Therapeutix Inc’s market cap is €1.61B.
When is Ocular Therapeutix Inc’s upcoming earnings report date?
Ocular Therapeutix Inc’s upcoming earnings report date is Aug 10, 2026 which is in 8 days.
How were Ocular Therapeutix Inc’s earnings last quarter?
Ocular Therapeutix Inc released its earnings results on May 05, 2026. The company reported -€0.347 earnings per share for the quarter, missing the consensus estimate of -€0.273 by -€0.074.
Is Ocular Therapeutix Inc overvalued?
According to Wall Street analysts Ocular Therapeutix Inc’s price is currently Undervalued.
Does Ocular Therapeutix Inc pay dividends?
Ocular Therapeutix Inc does not currently pay dividends.
What is Ocular Therapeutix Inc’s EPS estimate?
Ocular Therapeutix Inc’s EPS estimate is -0.34.
How many shares outstanding does Ocular Therapeutix Inc have?
Ocular Therapeutix Inc has 218,960,360 shares outstanding.
What happened to Ocular Therapeutix Inc’s price movement after its last earnings report?
Ocular Therapeutix Inc reported an EPS of -€0.347 in its last earnings report, missing expectations of -€0.273. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ocular Therapeutix Inc?
Currently, no hedge funds are holding shares in DE:0OT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocular Therapeutix Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€22.10 (198.70% Upside)
€22.10 (198.70% Upside)
Blogger Sentiment
Bullish
DE:0OT Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €316.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
80.46%
Trailing 12-Months
Company Description
Ocular Therapeutix Inc
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
0OT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and financial stability, with strong support from payers and successful trial execution. However, challenges such as market pricing pressure and potential enrollment difficulties in diabetic retinopathy trials were noted.View all DE:0OT earnings summaries0OT Stock 12 Month Forecast
Average Price Target
€22.10
▲(198.70% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
RegenXBio
―
Tarsus Pharmaceuticals
―
Oculis Holding
―
Aura Biosciences Inc
―